Editas Medicine : Corporate Effectiveness Report April 2026 (b08b29)

Published: 2026-04-17 10:18:09 ET EDIT

Published on 04/17/2026 at 10:18 am EDT

Addressing ESG & Long-term Sustainability

April 2026

A MESSAGE FROM

PRESIDENT & CEO

At Editas Medicine, our mission has always been to harness the power and potential of CRISPR gene editing to develop transformative medicines for people living with serious diseases. More than a decade after the discovery of this groundbreaking technology, we are increasingly seeing the potential of gene editing translate into meaningful scientific and clinical progress and outcomes for patients.

In 2025, we took an important step forward in our strategy to be a leader in transformative in vivo gene editing with the introduction of our lead development candidate, EDIT-401. This experimental, potential best-in-class, one-time in vivo CRISPR gene editing medicine is designed to significantly reduce LDL cholesterol (LDL-C) levels and has the potential to transform the treatment paradigm for hyperlipidemia. In preclinical studies, EDIT-401 demonstrated significantly reduced mean LDL-C levels of over 90 percent - far exceeding the reductions typically achieved by current therapies. If successful in clinical development, EDIT-401 could offer patients an economical, one-time treatment that delivers durable, lifelong reductions in cardiovascular risk.

Cardiovascular disease remains the leading cause of death worldwide, and elevated LDL-C, or hyperlipidemia, is a high prevalent disease affecting over 70 million patients in the United States alone. The promise of EDIT-401 illustrates the broader potential of gene editing: the opportunity to address common and serious diseases in ways that were not previously possible. We are now advancing EDIT-401 toward the clinic, with the goal of generating early human proof-of-concept data by the end of 2026.

While EDIT-401 represents our lead clinical priority, we remain encouraged by progress across our broader pipeline. Our teams continue advancing programs in hematopoietic stem cells while also building the scientific foundation for a broader in vivo gene editing portfolio.

This progress reflects our broader vision for Editas: to be a leader in in vivo gene editing, and our commitment to improving the lives of those impacted by serious diseases is our core focus. By combining our expertise in CRISPR gene editing with our differentiated upregulation strategy, we are working to develop medicines that have the potential to be first- or best-in-class therapies across a range of serious diseases.

Our progress is made possible by the dedication and expertise of our employees. Across research, development, and operations, the Editas team is united by a shared commitment to advancing our science and our mission. We strive to maintain a culture grounded in collaboration, integrity, and inclusion, where diverse perspectives strengthen innovation and help ensure we remain focused on the longterm impact of our work.

Strong governance and responsible corporate stewardship remain central to how we operate as a company. Our leadership team and Board of Directors are committed to transparency, ethical conduct, and long-term value creation as we continue advancing our pipeline and expanding the potential of gene editing medicine.

On behalf of the entire Editas team, thank you for your continued interest and support. We look forward to sharing further updates as we advance EDIT-401 toward the

clinic and continue working to deliver transformative gene editing medicines.

…we are working to develop medicines that have the potential to be first- or best-in-class therapies across a range of serious diseases."

Differentiated Upregulation Strategy

Novel therapeutic mechanisms unlocked by functionally upregulating protein expression

A leader in transformative

in vivo gene editing

Delivery to Target Tissues

Transformative Therapeutic Potential

Delivery platform enables precise delivery of in vivo gene editing medicines across tissue types (liver and others)

Address significant unmet needs via

one-time, durable treatment with meaningful

patient and broader healthcare system impact

EDIT-401: Potential to Transform the Hyperlipidemia Treatment Landscape

A potential best-in-class therapy with unprecedented >90% mean reduction in LDL-C in non-human

primates1, on track to achieve early human proof-of-concept data by end of 2026

LDL-C, low-density lipoprotein cholesterol

1. Editas Medicine. Data on file. 4

Seek out opportunities to learn from the communities we aim to create a treatment option for and continue to bring their voices into decision making and drug development planning.

ENGAGE REGULARLY

Health and treatment is deeply personal, and there are similarities and differences across diseases, and among individuals affected by the same disease. It is critical that we listen and understand diverse perspectives.

LISTEN ACTIVELY

We are optimistic about the promise of gene editing, yet there is still much to be learned. Through transparent communication about Editas Medicine and our approach to developing medicines, we hope to ensure the expectations we set are realistic.

ENGAGE

AUTHENTICALLY

Our goal is to implement an executive compensation program that attracts and retains qualified and talented executives, motivates such executives to achieve our business goals and rewards them for short- and long-term performance with a simple and clear compensation structure.

Maintain and evaluate annually an industry-specific peer

group for benchmarking pay

Review annually our compensation strategy to ensure target pay is based on market norms

Balance short- and long-term incentives

(through annual cash bonuses and equity awards)

Maintain a compensation recovery or "clawback" policy

Use multiple performance measures to determine incentive payouts

Engage an independent compensation consultant

WE WE

DO DON'T

No employment agreements that guarantee a certain compensation level or employment term

No guaranteed annual salary increases or guaranteed bonuses

No single-trigger vesting in connection with a change-in-control for equity awards

No excessive executive perquisites or personal benefits

No hedging or pledging or speculative transaction in our securities

No re-pricing of equity awards without stockholder approval

No excise tax gross-ups

2025 Target Executive Compensation

1 Ms. Parison's initial annual base salary for 2025 was $340,000 but was increased to $415,000 in connection with her promotion in March 2025 to Chief Financial Officer. For purposes of this chart,

her annual base salary following promotion has been annualized. 7

Jessica Hopfield, Ph.D.

Independent director since 2018

Principal,

J. Hopfield Consulting

Bernadette Connaughton

Independent director since 2021 Former President, Intercontinental, Bristol Myers Squibb

Andrew Hirsch

Independent director since 2017

President & CEO, C4 Therapeutics

Elliott Levy, M.D.

Independent director since April 2023

Venture Partner,

5AM Venture Management, LLC

Gilmore O'Neill, M.B., M.M.Sc.

President and CEO,

Editas Medicine

David Scadden, M.D.

Independent director since 2019

Gerald & Darlene Jordan Professor of Medicine Harvard University

EDITAS COMMITTEES

NAME & AGE

OTHER PUBLIC DIRECTORSHIPS

NCG

OLC

Andrew Hirsch, 55

C4 Therapeutics (CCCC)

Bernadette Connaughton, 67 Halozyme Therapeutics (HALO)

Jessica Hopfield, 61

Chair

Insulet Corporation (PODD)

Elliot Levy, 67 NuCana plc (NCNA)

David Scadden, 73 Agios Pharmaceuticals (AGIO)

Gilmore O'Neill, 61 None

A=Audit Committee

YEARS

AVERAGE AGE OF BOARD MEMBER

YEARS

AVERAGE TENURE

ON EDITAS' BOARD

WOMEN

NCG=Nominating and Corporate Governance Committee OLC=Organization, Leadership and Compensation Committee

MEMBER

CHAIR

Experienced Team Focused on Delivering Shareholder Value

Gilmore O'Neill, M.B, M.M.Sc.

Chief Executive Officer

Prior experience: Sarepta Biogen

Brieana Buckley, PharmD, MS

SVP, Development and Program Leader

Prior experience: Rhythm Biogen Bioverativ Sanofi

Linda Burkly, Ph.D.

Chief Scientific Officer

Prior experience: Biogen Lightstone Ventures

Exo Therapeutics

Damien Grierson

SVP, General Counsel

Gates Cooley A&O Sherman

Fidelity Jefferies

Prior experience: American Renal Associates K&L

Frank Panaccio

Chief Business Officer

Prior experience: Parexel Lumanity

Amy Parison

Chief Financial Officer

Prior experience: Rubius Therapeutics Vertex

PWC

Gregory Whitehead

Chief Technical and Quality Officer

Prior experience: Rubius Therapeutics bluebird bio Dendreon

Tom Love

VP, People

Prior experience: Kymera forma Therapeutics

Randstad Sourceright

Our governance structure strives to ensure independent oversight of an experienced management team and protection of long-term stockholder value

Board-level oversight of material enterprise risks

Management gives periodic reports to the Board or its Committees on cybersecurity risks

Clawback policy and clawback

provisions in equity awards

Prohibition on hedging and pledging shares of company stock by executive officers and directors

Commitment to Board refreshment, with a robust director nominee selection process

Mandatory retirement age of 75

Codified commitment to include a diverse range of qualified professions for nominee selection

BEST PRACTICES

REFRESHMENT

INDEPENDENCE

STOCKHOLDER RIGHTS

Supermajority of independent directors

Separate Board Chair and CEO roles

100% independent Board committees

Regular executive sessions of

independent directors

Annual Board and committee evaluations

Overboarding limits for directors

Annual "say-on-pay" vote

One single voting class of stock

Proactive annual stockholder engagement program

No "poison pill"

GREEN FACILITIES

Electrical systems designed for optimal performance and sustainability.

Low-emitting, partially recycled materials installed throughout facilities.

Use of energy saving equipment; automatic lighting shutoff controls to help lower energy usage.

Daylight and motion sensors allow full spectrum of natural light; LED fixtures used only when necessary.

ENERGY & WATER CONSERVATION

High efficiency water fixtures.

High efficiency mechanical and laboratory equipment.

High efficiency windows reduce solar heat gain.

Energy efficient hot water boilers.

State of the art wastewater control system.

Effluent is monitored and treated

with acid or base prior to release.

Sink wastewater recycled back to washrooms.

WASTE MANAGEMENT

Responsible biowaste and

chemical waste disposal.

Lab sustainability initiatives for recycling lab consumable plasticware.

All lab sink waste goes directly to separated storage tanks for specialized disposal.

Recycle batteries through third party vendor.

Our success is based on good science, and good science is based on good people working in a safe and collaborative environment

Editas employees, or Editors, are the fuel that drives our progress. Facilitating a culture that gives each Editor an opportunity to succeed is inherently based on important values that we strive to promote, as well as our ability to attract, retain, develop and motivate new talent. To do this, Editas offers employment packages, resources, and tools to foster a diverse and motivated workforce.

Employment salary and bonus packages promoting well-being, including healthcare, retirement planning and flexible time off.

Opportunities for equity ownership, including stock-based compensation awards and an employee stock purchase plan.

Work/Life balance arrangements including core hours and flexible work arrangements.

Regular benchmarking against industry peers to ensure Editas remains competitive and attractive to potential new hires.

Development programs enabling continued learning and professional growth, including peer mentorship programs and access to LinkedIn Learning classes.

Individual goal setting process, including regular conversations between employees and managers, promoting individual development and career growth.

The Editas Culture Committee is an employee-led group that works to ensure our day-to-day culture reflects our company values through learning opportunities, community, teambuilding events and forums for all editors.

We work together with integrity and joy, under the framework of our collective goal to develop transformative medicines for people living with serious diseases around the world.

The program brings people together through diverse forums and events,

including:

Philanthropic activities to support our local community, such as toy and clothing drives and patient advocacy support through participation in community events in our therapeutic areas of focus.

Employee focused initiatives to improve engagement and recognition and

to foster a culture of continuous learning and development.

Social events and celebrations including Lunar New Year, Olympics and World Cup celebrations, and other events throughout the year.

Corporate sponsorship and employee participation in the Prouty charity bike ride and JP Morgan Corporate Challenge.

Green initiatives focused on improving sustainability and reducing waste.

PILLARS of EDITAS CULTURE

PERFORMANCE & ENGAGEMENT

HEALTH & WELLNESS

PATIENT ADVOCACY & COMMUNITY

SOCIAL & FUN

Editas routinely reviews representational data and identifies a diverse pool of candidates for all job openings to ensure we remain an inclusive culture that continues to strengthen through diversity

Senior Management

All Editas Medicine Employees

37%

Women

48%

Women

Gender Diversity

37%

Minority

44%

Minority

Ethnic/Racial Diversity

Information as of December 31, 2025

Senior management reflects Director level and higher 15

GOVERNANCE, RISK, & COMPLIANCE

CYBER RESILIENCE & THREAT DEFENSE

Strong identity security including single sign-on, multi-factor authentication, and controlled privileged access to corporate and research systems.

Advanced endpoint protection and detection securing systems accessing company data.

Expanded vulnerability management resulting in an 83% reduction in high-risk vulnerabilities.

Encryption protecting sensitive data in transit and at rest.

24/7 threat monitoring through a managed Security Operations Center.

24/7 security operations response for rapid incident investigation and remediation.

Formal Incident Response program with defined escalation procedures and coordination with executive leadership and external partners.

Enhanced security awareness program with 31% reduction in phishing clicks and 81% increase in reporting.

Comprehensive cybersecurity program led by an experienced Chief Information Security Officer with deep biotechnology industry experience and expertise.

Risk-based cybersecurity program aligned with the NIST Cybersecurity Framework.

Annual independent penetration testing to identify and remediate security weaknesses.

Governance framework for responsible AI use, including policy, oversight committee, and application review process.

PROTECTING SCIENTIFIC INNOVATION

Our safety objective is to facilitate a safe work environment for employees, contractors and third-parties

TRAINING SAFETY PRECAUTIONS

Fire extinguishers, emergency showers, eye wash stations, spill kits, first aid kits and

Mandatory safety training for every employee

Mandatory annual lab safety training for lab employees

Optional training for CPR/AED

Employees working in the BL2 lab are required to wear a lab coat, safety glasses and gloves at all times

Semi-annual evacuation drills

AED machines throughout the buildings and

laboratories

All biosafety cabinets and fume hoods are certified annually

Employees are offered free of charge Hepatitis B three shot series, titer, and booster. Additionally, we have annually onsite Flu Vaccine Clinic, where employees are offered free of charge flu shots.

Safety glasses clinics are held quartertly, free of charge to full-time employees to get prescription and non-prescription safety glasses

Disclaimer

Editas Medicine Inc. published this content on April 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 17, 2026 at 14:17 UTC.